Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer

The Unanticipated Real-World Clinical Experience

Darren M. C. Poon; Kuen Chan; S. H. Lee; T. W. Chan; Henry Sze; Eric K. C. Lee; Daisy Lam; Michelle F. T. Chan


BMC Urol. 2016;16(12) 

In This Article


The present study reported the unanticipated short survival after AA in chemo-naïve patient outside clinical trial setting. The overall survival was particularly short in those with visceral diseases, and further clinical trial for AA in this subgroup of patients is warranted. In contrast, AA was well tolerated and efficacious in mCRPC patients with prior chemotherapy. AA resulted in comparable pain control in both groups of patients. PSA response, in particular present within the first 3 months after AA, could serve as a prognostic biomarker for survival outcome and may have a potential role in selecting patients for additional or alternative treatment earlier in future clinical trial.